Cargando…
Identification of Phenylpyrazolone Dimers as a New Class of Anti‐Trypanosoma cruzi Agents
Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse eff...
Autores principales: | Sijm, Maarten, Siciliano de Araújo, Julianna, Ramos Llorca, Alba, Orrling, Kristina, Stiny, Lydia, Matheeussen, An, Maes, Louis, de Esch, Iwan J. P., de Nazaré Correia Soeiro, Maria, Sterk, Geert Jan, Leurs, Rob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771560/ https://www.ncbi.nlm.nih.gov/pubmed/31319019 http://dx.doi.org/10.1002/cmdc.201900370 |
Ejemplares similares
-
Structure‐Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi
por: Sijm, Maarten, et al.
Publicado: (2020) -
Structure Activity Relationship of N-Substituted Phenyldihydropyrazolones Against Trypanosoma cruzi Amastigotes
por: Sijm, Maarten, et al.
Publicado: (2021) -
Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies
por: Soeiro, Maria de Nazaré C, et al.
Publicado: (2011) -
Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection
por: da Silva, Cristiane França, et al.
Publicado: (2017) -
In vitro and in silico analysis of imatinib analogues as anti-Trypanosoma cruzi drug candidates
por: Nesic de Freitas, Luca S. F., et al.
Publicado: (2023)